Merck (MRK) is in talks to buy Revolution Medicines (RVMD), a cancer drugmaker with a market capitalization of nearly $19B, said Financial Times. Other large pharmaceutical groups were still circling the Redwood City-based biotech and another suitor might yet prevail, though Merck has been pursuing an acquisition of Revolution Medicines, people familiar with the matter said. A tie-up would be at least several weeks away, the sources added.
Claim 70% Off TipRanks Premium
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RVMD:
- Immuneering updated 12-month data for atebimetinib ‘encouraging,’ says Leerink
- Revolution Medicines: Breakthrough-Backed G12D RAS Franchise Strengthens Bullish Risk‑Reward and Supports Buy Rating
- Revolution Medicines announces FDA BTD to zoldonrasib
- Revolution Medicines: Standalone Strength and Strategic M&A Upside Justify Buy Rating
- Revolution Medicines down 15% in after-hours after AbbVie denies takeover talks